^
Association details:
| Biomarker: | FGFR2 N549K |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) + pifusertib (TAS-117) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 661: Synergistic antitumor activity of futibatinib, an FGFR1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in FGFR-deregulated cancer models
Published date:
05/15/2020
Excerpt:
Effects of futibatinib plus TAS-117 were investigated in human endometrial FGFR2-N549K-mutated AN3CA cancer cells and small-cell lung cancer FGFR1-amplified DMS114 cells...Futibatinib and TAS-117 synergistically increased cell death and decreased cell growth in AN3CA (CI<0.40) and DMS114 (CI<0.40) cells, respectively....Our findings suggest that futibatinib plus TAS-117 has synergistic antitumor effects in FGFR-aberrant tumors.
DOI:
10.1158/1538-7445.AM2020-661
